Michael Gibney
Senior Editor & Writer | LinkedInMichael Gibney is a senior writer and editor for PharmaVoice. Before that, he covered the pharmaceutical industry as a healthcare reporter for three and a half years at S&P Global Market Intelligence and served as an editor at FiercePharma and FierceBiotech. Besides industry reporting, Michael has also covered science, wildlife and environmental issues as well as local news in Connecticut and Montana. A graduate of Bucknell University and the University of Missouri Journalism School, he is based in the Washington, D.C., area where you’ll find him hiking with two retired racing greyhounds, finding local breweries and grilling in the backyard.
275 articles by Michael Gibney
-
Inside AstraZeneca’s long-game strategy in lung cancer
Aug. 7, 2025 -
Let’s make a deal? Big Pharma execs express varying views on their M&A future
Aug. 5, 2025 -
Merck & Co. assembles an Alzheimer’s comeback with a next-gen precision focus
Aug. 1, 2025 -
From the bench: Researchers make NIH-funded preclinical strides in mRNA and obesity
July 25, 2025 -
Novartis’ Zolgensma sales fall again as gene therapy market woes persist
July 22, 2025 -
J&J accelerates past Stelara’s fall with better-than-expected portfolio growth
July 17, 2025 -
Biotech IPO momentum gained steam last year, but market ‘turmoil’ has slowed the train again
July 15, 2025 -
Pricing watchdog will take on the rising cost of drugs at launch
July 10, 2025 -
Is biopharma dealmaking getting hot again?
July 8, 2025 -
AI’s ‘massive transition’ in biopharma shapes leadership mindsets — tension and all
July 1, 2025 -
Biopharma is on edge about NIH funding cuts and what the future holds for research
June 26, 2025 -
How a Big Pharma veteran looks to stand out in biotech as a unique ‘drug hunter’
June 24, 2025 -
Biotech’s turning point: for every challenge, an opportunity in disguise
June 20, 2025 -
Can ‘reputational pull’ save biotech from pharma’s image problem?
June 12, 2025 -
The former Wall Street analyst shaping Novartis’ big-picture strategy
June 10, 2025 -
With ADCs on the rise, drugmakers embrace a new oncology pillar
June 6, 2025 -
How leading oncology drugmakers set the stage for future advances
June 3, 2025 -
With new Alzheimer’s blood test cleared, a potential vaccine could be on the horizon
May 28, 2025 -
Turning the page: Novo’s CEO transition reflects Big Pharma’s era of change
May 22, 2025 -
A new CFO tasked with taking ‘scrappy’ Editas from last year’s layoffs into new gene editing territory
May 15, 2025 -
With the breakneck speed of cancer breakthroughs, oncologists feel left behind. Can Big Pharma chime in?
May 13, 2025 -
Alnylam keeps pushing the rare disease paradigm as RNAi promises even wider indications
May 8, 2025 -
On tariffs and pricing, Big Pharma CEOs are waiting out the storm while planning for the worst
May 6, 2025 -
Can real-world evidence bear some of the burden left by NIH cuts? This CEO sees an opportunity.
May 1, 2025 -
US backlash against mRNA vaccines could hinder scientific progress
April 29, 2025